Transave
Monmouth Junction
About Transave
Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $58.5M
- Funding stage: M&A
- Last round: Debt Financing (Jun 2010)
- Website: transaveinc.com
Industries & Categories
Biotechnology, Health Care, Medical Device
Canonical: https://fsome.com/organization/transave-1458695 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.